Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefylti is CuraTeQ’s first biosimilar to receive this positive opinion. Three additional biosimilars are currently under review with EMA and UK-MHRA, expected to be available next year.
Related Posts
Now, BEML aims to start exporting Vande Bharat, metro trains in coming years
BEML Ltd intends to prioritize the rollout of Vande Bharat trains domestically before targeting export markets next year. The company is looking to secure export […]
HDFC Bank sells Rs 6,000 crore home loans
HDFC Bank has sold a housing loan portfolio of Rs 6,000 crore to several state-controlled banks and car loans worth Rs 9,060 crore via pass-through […]
Uber drivers at record high as people record high
- staff
- May 7, 2022
- 0
Minima hic aspernatur mollit egestas ultricies, nisl, posuere corporis fames dolor justo! Aptent, eos eligendi curabitur totam eros malesuada malesuada! Perferendis, turpis justo ipsam tempus […]